ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

Core Viewpoint - ADC Therapeutics will host a conference call on March 10, 2026, to report financial results for Q4 and the full year 2025, along with operational updates [1]. Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs), focusing on transforming treatment for patients with its portfolio, including ZYNLONTA (loncastuximab tesirine-lpyl) [1]. - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [1]. - The company is headquartered in Lausanne, Switzerland, with operations in New Jersey, and is committed to innovation in ADC development from clinical to commercialization [1]. Financial Results Announcement - The conference call will take place at 8:30 a.m. EDT, and participants are encouraged to join 10 minutes early [1]. - A live webcast will be available on the ADC Therapeutics website, with an archived version accessible for 30 days post-call [1].